Basit öğe kaydını göster

dc.contributor.authorDoganozu, Ersin
dc.contributor.authorSahin, Ilker
dc.contributor.authorKaracaglar, Emir
dc.contributor.authorHasirci, Senem Has
dc.contributor.authorBuldanli, Mehmet Zeki
dc.date.accessioned2020-07-28T13:06:32Z
dc.date.available2020-07-28T13:06:32Z
dc.date.issued2019
dc.identifier.issn0010-8650en_US
dc.identifier.urihttp://e-coretvasa.cz/pdfs/cor/2019/06/10.pdf
dc.identifier.urihttp://hdl.handle.net/11727/4802
dc.description.abstractAtrial fibrillation is the most common rhythm disorder worldwide. Oral anticoagulants are used in the treatment of atrial fibrillation. Non-vitamin K oral anticoagulants have been used more often because of the fact that they are more effective and safer than conventional warfarin therapy. The absence of antidote in the majority of new generation oral anticoagulants leads to some difficulties in clinical usage. Idarucizumab, a recently introduced drug, is used in reversing the dabigatran effect in cases of lethal bleeding or acute surgery and invasive procedures. However, little data are available on the efficacy and safety of idarucizumab in geriatric patients. Here, we present a case of the successful administration of idarucizumab in a geriatric patient with incarcerated bowel hernia.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.crvasa.2018.09.008en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulantsen_US
dc.subjectAntidotesen_US
dc.subjectAtrial fibrillationen_US
dc.titleIdarucizumab administration in a patient with incarcerated bowel herniaen_US
dc.typearticleen_US
dc.relation.journalCOR ET VASAen_US
dc.identifier.volume61en_US
dc.identifier.issue6en_US
dc.identifier.startpage623en_US
dc.identifier.endpage624en_US
dc.identifier.wos000503177200011en_US
dc.identifier.scopus2-s2.0-85054810912en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster